Abstract
Purpose: We have recently reported EBV+ B-cell lymphoproliferative disorders (LPD) occurring predominantly in elderly patients, which shared features of EBV+ B-cell neoplasms arising in the immunologically deteriorated patients despite no predisposing immunodeficiency and were named as senile or age-related EBV+ B-cell LPDs. To further characterize this disease, age-related EBV+ B-cell LPDs were compared with EBV-negative diffuse large B-cell lymphomas (DLBCL). Experimental Design: Among 1,792 large B-cell LPD cases, 96 EBV+ cases with available clinical data set were enrolled for the present study. For the control group, 107 patients aged over 40 yearswith EBV-negative DLBCL were selected. We compared clinicopathologic data between two groups and determined prognostic factors by univariate and multivariate analysis. Results: Patients with age-related EBV+ B-cell LPDs showed a higher age distribution and aggressive clinical features or parameters than EBV-negative DLBCLs: 44% with performance status >1, 58% with serum lactate dehydrogenase level higher than normal, 49% with B symptoms, and higher involvement of skin and lung. Overall survival was thus significantly inferior in age-related EBV+ group than in DLBCLs. Univariate and multivariate analyses further identified two factors, B symptoms and age older than 70 years, independently predictive for survival. A prognostic model using these two variables well defined three risk groups: low risk (no adverse factors), intermediate risk (one factor), and high risk (two factors). Conclusions: These findings suggest that age-related EBV+ B-cell LPDs constitute a distinct group, and innovative therapeutic strategies such as EBV-targeted T-cell therapy should be developed for this uncommon disease.
| Original language | English |
|---|---|
| Pages (from-to) | 5124-5132 |
| Number of pages | 9 |
| Journal | Clinical Cancer Research |
| Volume | 13 |
| Issue number | 17 |
| DOIs | |
| Publication status | Published - Sep 1 2007 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group : A studyof 96 patients. / Oyama, Takashi; Yamamoto, Kazuhito; Asano, Naoko; Oshiro, Aya; Suzuki, Ritsuro; Kagami, Yoshitoyo; Morishima, Yasuo; Takeuchi, Kengo; Izumo, Toshiyuki; Mori, Shigeo; Ohshima, Koichi; Suzumiya, Junji; Nakamura, Naoya; Abe, Masafumi; Ichimura, Koichi; Sato, Yumiko; Yoshino, Tadashi; Naoe, Tomoki; Shimoyama, Yoshie; Kamiya, Yoshikazu; Kinoshita, Tomohiro; Nakamura, Shigeo.
In: Clinical Cancer Research, Vol. 13, No. 17, 01.09.2007, p. 5124-5132.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group
T2 - A studyof 96 patients
AU - Oyama, Takashi
AU - Yamamoto, Kazuhito
AU - Asano, Naoko
AU - Oshiro, Aya
AU - Suzuki, Ritsuro
AU - Kagami, Yoshitoyo
AU - Morishima, Yasuo
AU - Takeuchi, Kengo
AU - Izumo, Toshiyuki
AU - Mori, Shigeo
AU - Ohshima, Koichi
AU - Suzumiya, Junji
AU - Nakamura, Naoya
AU - Abe, Masafumi
AU - Ichimura, Koichi
AU - Sato, Yumiko
AU - Yoshino, Tadashi
AU - Naoe, Tomoki
AU - Shimoyama, Yoshie
AU - Kamiya, Yoshikazu
AU - Kinoshita, Tomohiro
AU - Nakamura, Shigeo
PY - 2007/9/1
Y1 - 2007/9/1
N2 - Purpose: We have recently reported EBV+ B-cell lymphoproliferative disorders (LPD) occurring predominantly in elderly patients, which shared features of EBV+ B-cell neoplasms arising in the immunologically deteriorated patients despite no predisposing immunodeficiency and were named as senile or age-related EBV+ B-cell LPDs. To further characterize this disease, age-related EBV+ B-cell LPDs were compared with EBV-negative diffuse large B-cell lymphomas (DLBCL). Experimental Design: Among 1,792 large B-cell LPD cases, 96 EBV+ cases with available clinical data set were enrolled for the present study. For the control group, 107 patients aged over 40 yearswith EBV-negative DLBCL were selected. We compared clinicopathologic data between two groups and determined prognostic factors by univariate and multivariate analysis. Results: Patients with age-related EBV+ B-cell LPDs showed a higher age distribution and aggressive clinical features or parameters than EBV-negative DLBCLs: 44% with performance status >1, 58% with serum lactate dehydrogenase level higher than normal, 49% with B symptoms, and higher involvement of skin and lung. Overall survival was thus significantly inferior in age-related EBV+ group than in DLBCLs. Univariate and multivariate analyses further identified two factors, B symptoms and age older than 70 years, independently predictive for survival. A prognostic model using these two variables well defined three risk groups: low risk (no adverse factors), intermediate risk (one factor), and high risk (two factors). Conclusions: These findings suggest that age-related EBV+ B-cell LPDs constitute a distinct group, and innovative therapeutic strategies such as EBV-targeted T-cell therapy should be developed for this uncommon disease.
AB - Purpose: We have recently reported EBV+ B-cell lymphoproliferative disorders (LPD) occurring predominantly in elderly patients, which shared features of EBV+ B-cell neoplasms arising in the immunologically deteriorated patients despite no predisposing immunodeficiency and were named as senile or age-related EBV+ B-cell LPDs. To further characterize this disease, age-related EBV+ B-cell LPDs were compared with EBV-negative diffuse large B-cell lymphomas (DLBCL). Experimental Design: Among 1,792 large B-cell LPD cases, 96 EBV+ cases with available clinical data set were enrolled for the present study. For the control group, 107 patients aged over 40 yearswith EBV-negative DLBCL were selected. We compared clinicopathologic data between two groups and determined prognostic factors by univariate and multivariate analysis. Results: Patients with age-related EBV+ B-cell LPDs showed a higher age distribution and aggressive clinical features or parameters than EBV-negative DLBCLs: 44% with performance status >1, 58% with serum lactate dehydrogenase level higher than normal, 49% with B symptoms, and higher involvement of skin and lung. Overall survival was thus significantly inferior in age-related EBV+ group than in DLBCLs. Univariate and multivariate analyses further identified two factors, B symptoms and age older than 70 years, independently predictive for survival. A prognostic model using these two variables well defined three risk groups: low risk (no adverse factors), intermediate risk (one factor), and high risk (two factors). Conclusions: These findings suggest that age-related EBV+ B-cell LPDs constitute a distinct group, and innovative therapeutic strategies such as EBV-targeted T-cell therapy should be developed for this uncommon disease.
UR - http://www.scopus.com/inward/record.url?scp=34548862043&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34548862043&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-06-2823
DO - 10.1158/1078-0432.CCR-06-2823
M3 - Article
VL - 13
SP - 5124
EP - 5132
JO - Clinical Cancer Research
JF - Clinical Cancer Research
SN - 1078-0432
IS - 17
ER -